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Abstract
Background: Individuals with opioid dependence have cognitive deficits during abuse period in
attention, working memory, episodic memory, and executive function. After protracted abstinence
consistent cognitive deficit has been found only in executive function. However, few studies have
explored cognitive function during first weeks of abstinence. The purpose of this study was to study
cognitive function of individuals with opioid dependence during early abstinence. It was
hypothesized that cognitive deficits are pronounced immediately after peak withdrawal symptoms
have passed and then partially recover.
Methods: Fifteen patients with opioid dependence and fifteen controls matched for, age, gender,
and verbal intelligence were tested with a cognitive test battery When patients performed worse
than controls correlations between cognitive performance and days of withdrawal, duration of
opioid abuse, duration of any substance abuse, or opioid withdrawal symptom inventory score
(Short Opiate Withdrawal Scale) were analyzed.
Results: Early abstinent opioid dependent patients performed statistically significantly worse than
controls in tests measuring complex working memory, executive function, and fluid intelligence.
Their complex working memory and fluid intelligence performances correlated statistically
significantly with days of withdrawal.
Conclusion: The results indicate a rather general neurocognitive deficit in higher order cognition.
It is suggested that cognitive deficit during early abstinence from opioid dependence is related to
withdrawal induced neural dysregulation in the prefrontal cortex and is partly transient.
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Background
When opioids are used chronically as pain relievers they
may cause mild cognitive deficits in attention, complex
working memory, and episodic memory [1,2]. So far,
there is no evidence that these effects would continue after
cessation of oral opioid medication [3]. However, when
opioids are abused, they are often used intravenously with
frequent high doses and in parallel with other drugs of
abuse. Not surprisingly, cognitive associations of chronic
opioid abuse are more pronounced than in medical use.
In studies concerning very recent or ongoing chronic opi-
oid abuse there is even some, though not consistent, evi-
dence for general intellectual decline [4,5]. More
consistently, there is evidence for deficits in attention,
working memory, memory, and executive function [6-8].
Again, the studies concerning abstinence from opioid
abuse show better cognitive function than during opioid
abuse [9-14]. However, there are important differences
between early and late opioid abstinence, and these need
more consideration. Vast majority of relapses back to opi-
oid abuse in out-patient treatment settings take place dur-
ing first weeks of abstinence [15,16]. Thus, the study of
cognitive function within this time is relevant.
During early opioid abstinence somatic signs of with-
drawal are first easily noticed and then gradually disap-
pear. These include flu-like symptoms and changes in
heart rate and blood pressure. The symptoms typically
peak within three days from the last dose of intravenous
heroin and within five days from the last dose of intrave-
nous buprenorphine [17,18]. Instead, during late absti-
nence, after first three weeks, somatic signs of opioid
withdrawal are seldom observed but drug craving may
still be present.
Early opioid abstinent patients often complain fatigue
and poor concentrating. In agreement with this a cascade
of neural dysregulations takes place during that time. The
cascade starts with abrupt downregulation of mu opiate
receptor activity together with elevation of gamma-ami-
nobutyric acid (GABA) and dynorphin release in the stria-
tum and the limbic system [19]. This is followed by
increased release of noradrenaline in the locus couruleus
and the bed nucleus of the stria terminalis paired with
excessive glutamate release in the hippocampus and the
anterior cingulate cortex. Marked reduction of dopamine
activity in the mesolimbic system and its projections has
an inverse relationship with a strong increase of
dopamine, noradrenaline and serotonin content in the
medial prefrontal cortex [20]. Finally, brain stress systems
are activated due to noradrenergic activation of cortico-
trophin releasing factor from the hypothalamus and the
amygdala [21] In concordance with this an elevation of
cortisol secretion takes place during early opioid absti-
nence [22]. Against this background, it is surprising that
cognitive function during early opioid abstinence has
been investigated only in one study.
In a study by Guerra et al. individuals with current heroin
abuse showed deficits in attention, working memory, epi-
sodic memory, and verbal fluency [9]. At retest 7–14 days
after admission to rapid detoxification treatment their
performance reached the level of controls. The results
indicate a rapid recovery of cognitive function. However,
practice effects were not controlled for.
There are more studies concerning cognitive function dur-
ing late opioid abstinence. In Gerra et al. study patients
with opioid abuse history were studied four months from
detoxification [10]. Patients with antisocial personality
disorder showed deficits in complex attention and in exec-
utive function. Other patients showed no deficits. In
Davis et al. study patients with six months of opioid absti-
nence showed no specific cognitive deficits [11]. In Lee
and Pau study previous heroin users with eight months of
abstinence as well as in Pau et al. study with fourteen
months of abstinence showed deficit in executive function
[12,13] In Mintzer et al. study patients with nine months
of opioid abstinence showed normal cognitive perform-
ance expect in one task combining visual attention and
flexibility [14]. Thus, in studies concerning late opioid
abstinence executive function deficit has been most con-
sistent finding.
The main aim of the present study was to explore cogni-
tive function of individuals with opioid dependence dur-
ing early abstinence in comparison to normal controls.
The groups were matched for age, gender, and verbal intel-
ligence (VIQ). On the basis of opioid withdrawal related
neural cascade and earlier research deficits in working
memory, episodic memory, and in executive function
were expected. Non-optimal catecholamine levels in pre-
frontal cortex may cause working memory deficit, espe-
cially when together with hypercortisolism [23,24].
Executive function may be impaired because it is depend-
ent on optimal noradrenaline function [25,26]. Also
learning and memory may be impaired. Chronic exposure
to opiates reduces the birth of new neurons in the dentate
gyrus of the adult hippocampus, and this is known to
affect learning and memory [27,28]. In addition, fluid
intelligence was measured. It is known to be more sensi-
tive to frontal lobe dysfunction than conventional execu-
tive function tests [29-31]. Therefore, it was hypothesized
that also fluid intelligence performance would be
reduced.
Our second aim was to explore if cognitive deficits in early
opioid abstinence are at least partially transient. Opioid-
induced neuronal changes in the prefrontal cortex, hip-
pocampus, or thalamus show signs of recovery within firstBMC Psychiatry 2006, 6:9 http://www.biomedcentral.com/1471-244X/6/9
Page 3 of 10
(page number not for citation purposes)
month of cessation of opioid treatment [32]. Abnormal
elevations of neural activity in the striatum and the amy-
gdala reduce within 1 – 2 first weeks from opioid with-
drawal [19]. In concert with this, high cortisol levels
resume to normal levels within first weeks of abstinence
[33]. Normal function of the catecholaminergic and
GABAergic systems after few months of opioid abstinence
has been reported with some exceptions concerning psy-
chiatric co-morbidity [10,34-36]. Thus, the hypothesized
cognitive deficits may show recovery. Therefore, we ana-
lyzed correlations between cognitive performance and
days of withdrawal; and between cognitive performance
and subjective opioid withdrawal symptoms, whenever
opioid dependent individuals performed worse than con-
trols. In addition, as long-term neurotoxicity related to
substance abuse is possible, correlations between dura-
tion of opioid abuse or any substance abuse and cognitive
performance were analyzed whenever patients performed
worse than controls.
Methods
The participants of the study included 15 individuals with
opioid dependence who were voluntary inpatients from
Helsinki University Central Hospital drug detoxification
unit and 15 controls. All participants were between ages
20 – 50 years. Participants with uncontrolled mixed sub-
stance abuse, acute alcohol abuse, or acute axis I psychiat-
ric morbidity according to Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) not related to sub-
stance were excluded. Also participants with severe brain
injury, chronic neurological disease, with history of epi-
leptic seizures, with human immunodeficiency virus
(HIV), primary organic cognitive deficit, or magnetic
objects contraindicative for magnetic resonance imaging
(MRI) were excluded from the study. Each participant was
evaluated by brain MRI, and participants showing lesions
indicating vascular pathology or brain injury were
excluded. The study protocol was accepted by the Ethics
Committee of Helsinki University Central Hospital. A
written informed consent according to the Declaration of
Helsinki was obtained from all participants.
All participants with opioid dependence were voluntary
patients from a series of consecutive patients admitted for
potential methadone maintenance treatment. The
patients were hospitalized for two weeks in a drug with-
drawal unit before starting methadone substitution treat-
ment. The criteria for this in our institute were a minimum
age of 20 years, four years of documented opioid depend-
ence, and failure of institutional or long-lasting outpatient
opioid withdrawal. In the patient group there were several
cases for all variants of hepatic viruses (A, B, or C). How-
ever, none of these were in acute phase. All participants
that were studied for HIV were negative. One patient
refused to be tested for HIV. The patients had no neuro-
logical complains. Two patients either refused to be tested
or stopped inpatient treatment.
A control group matched for age, gender, and VIQ was
recruited from the staff of our institution. The VIQ match-
ing was based on Wechsler's revised intelligence scale
(WAIS-R) vocabulary subtest [37]. None of the controls
had abused illegal drugs, but all of them had taken alco-
hol on social occasions. However, none of them met the
criteria of abuse or dependence on alcohol. The controls
were screened by psychiatric interview of having no his-
tory of major psychiatric morbidity or substance abuse.
Demographic variables of the groups are presented in
Table 1. As a group the controls had more education than
participants with opioid dependence.
The dependence and other psychiatric diagnoses were
done according to the Structured Clinical Interview
(SCID) for DSM-IV axes I and II [38,39]. All patients met
the DSM-IV criteria for opioid dependence. Nine patients
also fulfilled the criteria for benzodiazepine dependence
and four for cannabis dependence. One patient had all
these three diagnoses. Self-reported recent month drug
abuse was consistent with urine screening results. Table 2
shows recent month drug abuse in the patient group.
During the inpatient period many participants with opi-
oid dependence showed current mood or anxiety disorder
symptoms. However, only two participants were classified
Table 1: Group demographics
Participants with opioid dependence (n = 15) Controls (n = 15) P-value
Age, years (M, SD) 31.6 (5.8) 31.3 (5.9) NS.
Gender: females/males 9/6 9/6 NS.
Verbal intelligence a(M, SD) 98.7 (8.9) 98.5 (10.1) NS
Education, years (M, SD) 11.6 (1.2) 13.9 (1.6) P < 0.001
Duration of any substance abuse, years (M, SD) 15.2 (6.1)
Duration of opioid abuse, years (M, SD) 8.6 (4.1)
Duration of withdrawal, days (M, SD) 9.6 (2.3)
Short Opiate Withdrawal Scale score (M, SD) 9.8 (5.7) (n = 13)
aEstimation based on WAIS-R Vocabulary score.BMC Psychiatry 2006, 6:9 http://www.biomedcentral.com/1471-244X/6/9
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as having other axis I diagnosis than substance-abuse.
Both of these were depressive disorders not otherwise
specified. When DSM-IV axis II diagnoses were evaluated,
all patients met criteria for at least one personality disor-
der. The most common of these was the antisocial person-
ality disorder, which was diagnosed in all except three,
who also had some features of antisocial personality dis-
order.
Cognitive tests
A battery of cognitive tests included tests of working mem-
ory, episodic memory, executive function, and fluid intel-
ligence. All tests were administered according to standard
instructions.
Working memory was measured by The Digit Span
subtest from the Wechsler Memory Scale-Revised (WMS-
R) and a computerized version of the Paced Auditory
Serial Addition Task (PASAT) from the FORAMENRehab
software package [40-42]. The Digit Span measures verbal
working memory storage in relatively simple form. In the
PASAT complex working memory functions are required:
continuous storage of previous number, rapid arithmeti-
cal processing, and executive control of interference from
previous items or from ongoing adding process. Presenta-
tion rate of a new number to be added with the previous
one was one in every 1.6 second.
Verbal memory was measured by The delayed Logical
Memory subtest of the WMS-R and the Rey Auditory Ver-
bal Learning Test (the RAVLT) [40,43]. To avoid ceiling
effect in the RAVLT only three learning trials of 15 word
list were presented. The sum of the first three RAVLT trials
was used as a parameter for immediate learning. Visual
memory was measured by the Benton Visual Retention
Test [44].
Executive function was measured using the modified
Stroop task and the Ruff Figural Fluency Test [45,46]. The
interference time of the Stroop task was calculated by sub-
tracting reading time of 50 non-colored words from nam-
ing time of 50 colors printed in a different color than the
one spelled by the letters by a procedure first described by
Dodrill [47]. Thus, both color naming speed and interfer-
ence from inhibition from not reading words are affecting
the result. According to current research this procedure
should be more prone to interference effect than subtract-
ing from color naming [48]. The RFFT is a design fluency
task measuring planning and fluency of action. A paper
containing a series of squares with five dots in each one is
presented. Then as many as possible unique figures are
drawn by connecting at least two dots with straight line in
each square.
Fluid intelligence was measured by the Culture Fair Intel-
ligence Test (CFIT) also known as Cattell's Culture Fair
test [49]. Version 2A was used. The CFIT includes a group
of visuo-spatial reasoning tasks. The performance of the
participant in these tasks reflects fluid or general intelli-
gence needed in highly demanding novel problem solving
situations. This test is sensitive to fluid intelligence deficit
due to various origins. Dissociations between preserved
standard intelligence measured by the Wechsler scales and
by the poor CFIT scores have been shown in frontal lobe
lesions as well as in normal ageing [30,50]
Procedure
The psychiatric examination and diagnosis were done by
trained psychiatrists at the detoxification unit. The day of
cognitive testing was randomly chosen from days between
5 to 15 days from the last opioid dose. Tests were pre-
sented alternating between difficult and easy ones, and
verbal and nonverbal ones, and memory and non-mem-
ory ones. To avoid fatigue, one pause was held during test-
ing. Patients showing positive urine drug screening at
initiation of withdrawal period were tested after negative
drug screening for other drugs than those prescribed for
them. On the test day morning at 8.00 patients completed
Table 2: Recent month drug abuse in patient group (number of patients)
Main opioid abused
Buprenorphine 10 Heroin 5
Opioid only 1
Opioid with occasional benzodiazepine 3
Opioid with frequent benzodiazepine 6 2
Opioid with frequent benzodiazepine and 
occasional cannabis
1
Opioid use with benzodiazepines
Opioid with frequent cannabis without other 
substances of abuse
11
Note: Occasional = five to ten days of abuse. Frequent = more than ten days of abuse. All who had abused mainly heroin within recent month did 
it were intravenously. All but two abused buprenorphine intravenously.BMC Psychiatry 2006, 6:9 http://www.biomedcentral.com/1471-244X/6/9
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the 10-item Short Opiate Withdrawal Scale (SOWS) [51]
measuring withdrawal symptoms. All patients were using
symptom relieving or other psychotropic medication on
the day of testing. Medication variables of the test day are
presented in Table 3. The brain MRI scans were evaluated
by two neuroradiologists. A consensus of opinion was
formed in each case. Analyses of MRI results are reported
separately [52].
Statistical analysis
Analysis of variance (ANOVA) was used to compare the
raw scores of each cognitive test. Statistical significance
was set at 0.05 (two-tailed). P-values of 0.05–0.1 were
considered as a statistical trend. Effect sizes were calcu-
lated with Cohen's d. Corrections for multiple compari-
sons were not applied due to seminal nature of this study
and the limited power afforded by small number of par-
ticipants. Group difference in education was not covaried
for, because the assumption of similar linear relation
between education and cognitive performance in both
groups needed for analysis of covariance (ANCOVA) was
not met. All participants with opioid dependence had
started substance abuse in their early teen years. Once the
substance abuse history begins, early-onset substance
abusers start to skip school lessons at primary school, get
poor grades, and only few of them get a diploma from sec-
ondary education. Thus, as a group, the participants with
opioid dependence had less education than their VIQ
comparable controls. Thus, group difference in education
does not give as reliable estimate about their primary
intellectual capacity than VIQ. Whenever participants
with opioid dependence performed significantly worse
than control participants correlations between cognitive
performance and variables of interest, were analyzed by
the Pearson product-moment correlation coefficient. Sta-
tistical analyses were done by SPSS statistical PC program,
version 11.0.
Results
Table 4 shows that participants with opioid dependence
performed significantly worse than control participants in
fluid intelligence, measured by the CFIT, in complex
working memory, measured by the PASAT, and in one
executive function test, the RFFT.
Analysis of correlations between inferior cognitive per-
formance and days of withdrawal showed statistically sig-
nificant results with fluid intelligence measured by the
CFIT performance and with complex working memory
measured by the PASAT (R = .65, P = 0.009 and R = .63, P
= 0.01, respectively). Figures 1 and 2 depict these correla-
tions. However, reduced figural fluency performance in
the RFFT and days of withdrawal showed no association
(R = -.01, NS). The highest correlations between years of
opiate abuse or years of any substance abuse and between
inferior cognitive performances were found for the RFFT
performance -.23 and -.31; respectively: Both of these
were statistically non-significant. The correlations
Table 3: Medication within last 24 h before testing in patient group
Medications used within 24 hours of test Number of patients Dose, range
Antidepressives 4 (26 %)
Doxepine 2 50 – 100 mg
Sertraline 1 150 mg
Venlaflaxine 1 150 mg
Anxiolytics, sedatives and hypnotics 
(Benzodiazepines)
15 (100%)
Diazepam 10 5 – 30 mg
Oxazepam 4 15 – 60 mg
Tematzepam * 4 20 – 40 mg
Zolpidem * 1 10 mg
Zopiclone * 1 15 mg
Neuroleptics † 10 (67%)
Chlorprotixine/Truxal 1 75 mg
Promazine 9 100 – 200 mg
Melperone 3 75 mg
Other opioid withdrawal symptom relievers 15 (100%)
Hydroxyzine 6 100 – 300 mg
Lofexidine 6 0.2 – 1.2 mg
Naproxen/Alpoxen 6 1000 – 1500 mg
* Used as a hypnotic the night before testing. † Used with anxiolytic indicationsBMC Psychiatry 2006, 6:9 http://www.biomedcentral.com/1471-244X/6/9
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between the SOWS score and inferior cognitive perform-
ance ranged from 0.08 to -0.13 (NS).
Discussion
Early abstinent opioid dependent individuals performed
worse than normal controls in complex working memory,
executive function, and fluid intelligence. Thus, the results
support our main hypothesis of reduced cognitive per-
formance in these areas during early opioid abstinence.
The effect sizes of the group differences in these areas are
similar or higher than the ones found in studies concern-
ing current drug abuse [53]. The high positive correlations
that were found between fluid intelligence performance
or complex working memory performance and days of
withdrawal support the hypothesis of transient cognitive
deficit. Although correlations do not imply causality, they
may give impetus for more detailed considerations.
If neurocognitive deficits related to opioid abuse are con-
sidered to reflect a rather permanent neurotoxicity of opi-
oid abuse, then the effect of abuse period under which the
study was done (ongoing abuse vs. early abstinence vs.
late abstinence) should be small. However, as reviewed in
the background section neural dysregulations are pro-
nounced during early opioid abstinence; and this is likely
to affect cognition. This conclusion is supported by com-
paring our complex working memory results to the results
by Mintzer et al study in which a two-back working mem-
ory task was employed [14]. In their study opioid depend-
ent patients treated with opioid agonist methadone
showed working memory deficit, whereas patients with
nine months of opioid abstinence showed normal per-
formance. Thus, there is some evidence that individuals
with current opioid use or under early opioid abstinence
show complex working memory deficit, whereas individ-
uals who have reached late opioid abstinence do not show
similar deficit. This is in agreement with the suggestion
that neurocognitive deficits related to several drugs of
abuse including opioids should be seen as recoverable
limitations of neuronal plasticity rather than as more per-
manent "lesion effect" [54].
The relevance of neurocognitive study results comes often
from dissociations found between different functions. In
this study three dissociations merit further consideration.
First, early opioid abstinent patients were inferior to con-
trols in fluid intelligence task though the groups were
matched for VIQ. According to functional neuroimaging
studies this indicates deficiencies in frontoparietal net-
works needed in several demanding cognitive task [55]
The second dissociation was found between deficient per-
formance in complex working memory task, the PASAT,
and normal or nearly normal episodic memory perform-
ance. Against our expectations there were no group differ-
ences in immediate or delayed free recall tasks. Thus, it is
possible that neural dysregulations in hippocampus dur-
ing opioid withdrawal may not affect episodic memory.
It has been suggested that stress system induced episodic
memory impairment needs more chronic stress system
abnormality than working memory impairment; and this
Table 4: Comparisons of individuals with opioid dependence and controls on cognitive measures using ANOVA
Controls (n = 15) Individuals with Opioid 
Dependence (n = 15)
Domain Mean ± SD (CI)a Mean ± SD (CI) F df d P
Test
Attention
PASAT 47.5 ± 7.8 (43.2 – 51.8) 36.1 ± 10.1 (30.4 – 41.7) 12.00 1,28 1.26 0.002
WMS-R Digit Span 15.4 ± 3.8 14.9 ± 2.7 0.15 1,28 0.15 NS
Memory
RAVLT, sum of learning trials 1–3 32.3 ± 6.1 28.9 ± 6.0 2.64 1, 28 0.56 NS
RAVLT, delayed recall 10.7 ± 2.8 9.0 ± 2.8 2.65 1, 28 0.61 NS
WMS-R Logical Memory, immediate 28.0 ± 5.5 25.9 ± 8.1 0.72 1, 28 0.30 NS
WMS-R Logical Memory, delayed recall 25.1 ± 6.6 22.3 ± 7.3 1.20 1, 28 0.40 NS
BVRT, number of right figures 7.4 ± 1.3 6.8 ± 1.6 0.88 1, 28 0.41 NS
Executive function
Stroop, modified interference time 24.5 ± 12.0 25.1 ± 8.8 0.30 1, 28 0.12 NS
RFFT, unique designs 86.3 ± 22.6 (73.9 – 98.8) 68.1 ± 21.2 (43.2 – 51.8) 5.22 1, 28 0.83 0.03
RFFT, perseverative errors 2.8 (2.6) 3.4 (2.9) 0.34 1,28 0.22 NS.
Fluid intelligence
CFIT 34.0 ± 3.8 (32.5 – 36.7) 30.4 ± 4.2 (28.0 – 32.8) 7.97 1, 27 0.90 0.009
a CI = confidence interval
Note: CFIT = Culture Fair Intelligence Test; PASAT = Paced Auditory Serial Addition Task; WMS-R = Wechsler Memory Scale-Revised; RAVLT = 
Rey Auditory Verbal Learning; BVRT = Benton Visual Retention Test; RFFT = Ruff Figural Fluency Test.BMC Psychiatry 2006, 6:9 http://www.biomedcentral.com/1471-244X/6/9
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would hold especially among young adults [56,57]. Dur-
ing early opioid abstinence high stress system activation
as shown by elevated cortisol level is common. It is espe-
cially pronounced among individuals with antisocial per-
sonality disorder [35]. Therefore, as nearly all patients
studied were young adults (mean 31.5 years) and most of
them (12/15) had antisocial personality disorder, ele-
vated stress system activation during early opioid absti-
nence may be related to the dissociation observed
between complex working memory and episodic mem-
ory.
The third dissociation was found between deficient com-
plex and normal simple working memory performance:
the PASAT and the Digit Span, respectively. In the PASAT
both storage and central executive components of work-
ing memory are needed [58]. The Digit Span task
demands especially storage of the several items and cen-
tral executive is involved to a lesser degree. Thus, we sug-
gest that central executive component of working memory
is impaired during early opioid abstinence while storage is
intact.
There are some studies indicating that executive function
deficit may be found during late opioid abstinence as well
[12,13]. This idea is in agreement with zero-correlation
found between days of withdrawal and reduced figural
fluency performance. In addition, the non-significant neg-
ative correlations between figural fluency performance
and duration of opioid abuse or any substance abuse (-.23
and -.31) are in line with earlier research showing negative
association between opioid abuse severity and figural flu-
ency performance [59]. A larger sample study concerning
the relationship between opioid abuse or other substance
abuse variables and fluency performance is warranted.
The positive correlations that were between impaired
complex working memory or fluid intelligence perform-
ances and days of withdrawal are in agreement with the
idea that the observed deficits in these domains may be
partly transient. It is known that high cortisol levels may
associate with working memory deficit [23,24]. It is also
known that during early opioid abstinence cortisol levels
are elevated but then start to normalize during second
week of abstinence [33]. Thus, we suggest that cognitive
deficit during early opioid abstinence may partly relate to
high brain stress system activation during that time, and
therefore is partly transient. In agreement with this idea, a
recent experimental study showed that chronic stress sys-
tem elevation leads to transient – not permanent – dys-
function – of prefrontal dopamine system [60]. The
authors suggest that this may negatively affect working
Correlation between complex working memory test per- formance and days of withdrawal among individuals with  early abstinence from opioid dependence Figure 2
Correlation between complex working memory test 
performance and days of withdrawal among individu-
als with early abstinence from opioid dependence 
Note: PASAT = Paced Auditory Serial Addition.
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memory. Interestingly, working memory and fluid intelli-
gence are highly associated [61].
Finally, the correlations found between opioid with-
drawal symptoms as measured by the SOWS and cogni-
tive performances were practically zero. It is possible that
the SOWS reflects mostly peripheral aspects of opioid
withdrawal syndrome.
Clinical implications
Higher order cognition and prefrontal cortex function are
closely related. It has been suggested that when prefrontal
cortex function gets "off line" in prolonged stressful situa-
tions more habitual responses start to regulate behavior
[62]. Thus, reduced higher order cognition and impulsive
behavior during early opioid abstinence are likely to be
associated. Therefore, screening of higher order cognitive
functions by highly sensitive task like the PASAT could be
used for treatment planning. In addition, pharmacologi-
cal and behavioral interventions to improve working
memory performance may improve opioid withdrawal
outcomes as well [63,64].
Limitations
The small number of participants reduces the power to
detect mild to moderate cognitive deficits. Previous ben-
zodiazepine abuse or cannabis abuse that was common
among our patient group may also affect the results of this
study. Long-term cannabis abuse and benzodiazepine
abuse both have adverse effect on cognitive function
[65,66]. Current benzodiazepine medication at test was
common. In normal population benzodiazepines have
adverse affect on several cognitive functions. On the other
hand, noradrenaline agonist lofexidine, which was given
to the patients of this study, may improve reduced work-
ing memory performance [63]. In our sample the fre-
quency of personality disorders, and especially antisocial
personality disorder was more common than known fre-
quencies of these disorders among substance abusers. This
also should be taken into account when comparing our
results with other studies. The group matching procedure
of our study was based on VIQ whereas in most other
studies the matching is based on education. Though
matching for VIQ or premorbid IQ is not totally excep-
tional in opioid abuse studies [6,11], this should be taken
into account when comparing our results with other stud-
ies. Finally, the suggestion for transient cognitive deficit
due to high stress system activation is very preliminary.
Longitudinal studies with relevant cognitive and neuroen-
docrine variables may determine if suggested associations
between these variables exist.
Conclusion
Fluid intelligence, working memory, and executive func-
tion deficit observed in opioid withdrawal patients during
first or second week from detoxification implicates a
rather general cognitive deficit. We suggest that cognitive
deficit during early opioid abstinence may be associated
with known opioid withdrawal related neural dysregula-
tions in the prefrontal cortex. Fortunately, relatively rapid
recovery of cognitive function during opioid abstinence
seems possible. Yet, the role of cognitive control during
the narrow gateway to long-term opioid abstinence needs
further studies.
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